argenx's Forte acquisition delivers coeliac trial win
argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.
Viatris builds in pain relief with $1.65bn Pacira purchase
As it waits for an FDA decision on one non-opioid pain drug, Viatris has its eye on two more, via a takeover bid for Pacira BioSciences.
Durability and earlier access could reshape diabetic retinop...
This year’s World Sight Day turns global attention to the scale of preventable vision loss
Changing Faces: Pharma and biotech hires, September 2026
There was plenty of movement at the top of pharma and biotech in September, with leadership changes spanning some of the industry’s biggest names.
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
UAE investment drives Middle East biopharma transformation a...
Exclusive analysis for World Health Expo (WHX) by Frost & Sullivan forecasts precision medicine growth of more than 10% in the Middle East over the ne
Europe's Largest Gathering for ADC Innovation
Taking place in London from 8-11 March 2027, the 17th World ADC London returns as Europe's largest annual gathering dedicated to the ADC community
PharmaMarketing Summit 2027 to Convene America's Top Pharmac...
Elite industry leaders will gather to address AI-driven engagement, launch excellence, and the future of market access at an exclusive, invitation-only event
3rd Annual Personalized Cancer Vaccine Summit 2026 | Decembe...
The 3rd Annual Personalized Cancer Vaccine Summit brings together leaders from across companies to share data-driven insights
CPHI Milan 2026 showcases new Sustainability Summit
The first-time event will bring delegates together to discuss sustainability challenges